Phase 2 trial of enfortumab vedotin plus pembrolizumab with selective bladder sparing for treatment of muscle-invasive urothelial cancer of the bladder

Hispanic/Latino and non-Hispanic BlAck patients treated with niRaparib and abiraterone acetate plus prednisone for Metastatic hOrmone sensitive prostate cancer with deleterious homologous recombinatioN repair alterations: a phase II, open label studY (HARMONY)  

ENHANCE (Elevated NKG2A and HLA-E Amplify NK/CD8 Checkpoint Engagers): A Phase 2 Trial of Durvalumab (MEDI4736) plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

TAGALONG Trial: Phase II Study of TAGraxofusp and Azacitidine With or Without Venetoclax in Newly Diagnosed Secondary AML after Previous Exposure to HypOmethylatiNG Agents

An Open Label, Phase II Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER2-Positive Breast Cancers

Phase I/II Study of Stereotactic Radiosurgery With Concurrent Administration of DNA Damage Response (DDR) Inhibitor (OLAparib) Followed by Adjuvant Combination of DuRvalumab (MEDI4736) and Physician’s Choice Systemic Therapy in Subjects With BreAst Cancer Brain Metastases

A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)

BRIDGET: Secondary BRain metastases prevention after Isolated intracranial progression on Trastuzumab/Pertuzumab or T-DM1 in patients with aDvanced human epidermal Growth factor receptor 2+ brEast cancer with the addition of Tucatinib

Observational basket trial to predict response to immune checkpoint inhibitors across solid tumors using a live tumor diagnostic platform (CYBRID-02)

Phase 2 study of novel SEQUEnced immunotherapy (pembrolizumab) with anti-angiogenesis and chemotherapy in advanced gastric and gastroesophageaL junction (GEJ) adenocarcinoma (SEQUEL)

Randomized Trial of Regorafenib in Combination with Pembrolizumab or Pembrolizumab Monotherapy for Patients with MSI-H Colorectal Cancer

A Phase Ib/II Study of Sotorasib Combined with Chemotherapy for Second Line Treatment of KRAS p. G12C Mutated Advanced Pancreatic Cancer

PhAse I/II StuDy of Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the BLADDER – (ADAPT-BLADDER) HCRN GU16-243

A Phase 2 Study of CAbozantinib in Combination With AtezolizumaB as NeoAdjuvant Treatment for Muscle-Invasive BladdEr Cancer (ABATE)

Phase II Trial of Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer (PLANE-PC)

NePtune: A Phase 2 Study of Neoadjuvant PARP Inhibition followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with BRCA1/2 Gene Alterations

Neoadjuvant Pembrolizumab for Muscle-Invasive Bladder Cancer with Selective Bladder Sparing

A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer (CANOPY)

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT)

A Phase II, Single Arm, Open Label, Multi-center Trial of Neoadjuvant Radiation and Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Previously Untreated Locally Advanced, Resectable, HPV Mediated Oropharynx Cancer

A Phase II Study Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination with Carboplatin in Extensive Stage Small Cell Lung Cancer. HCRN: LUN17-302

Randomized phase II study of durvalumab or durvalumab plus chemotherapy in Kras mutation positive and PD-L1 high (>/= 50%) NSCLC patients

MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer (MOZART)

DURABLE: Delayed or Upfront brain RAdiotherapy in treatment naïve lung cancer patients with asymptomatic or minimally symptomatic Brain metastases and rEarrangements

Phase II study of adagrasib + stereotactic radiosurgery (SRS) for patients with metastatic KRAS G12C-mutated NSCLC with untreated brain metastases

Phase 2, open label, multicenter study of pacritinib in relapsed/refractory T-cell lymphoproliferative neoplasms

A phase II study of pembrolizumab and mogamulizumab in advanced-stage, relapsed/refractory cutaneous T-cell lymphomas

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

A Single Arm Phase II Study with Safety Run-in of Peptide Receptor Radionuclide Therapy (PRRT) in Combination with Immunotherapy for Patients with Merkel Cell Cancer (iPRRT Study)

A Phase II Trial of Avelumab or Hydroxychloroquine with or without Palbociclib to Eliminate Dormant Breast Cancer (“PALAVY”)

Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study

A phase I/II, single arm, non-randomized study of ribociclib (LEE011), a CDK 4/6 inhibitor in combination with bicalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-024

Prospective assessment of patients with neuroendocrine tumors and current or prior history of carcinoid syndrome or diarrhea undergoing peptide receptor radionuclide therapy with or without telotristat ethyl (NET-PACS Trial) Big Ten Cancer Research Consortium BTCRC-GI19-400

A Phase II Study of Peri-Operative NovoTTF-200T(P) in Combination with Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI21-500

Phase 2 Study of Gemcitabine, Cisplatin, Quemliclustat (AB680) and Zimberelimab (AB122) during First-Line Treatment of Advanced Biliary Tract Cancers: Big Ten Cancer Research Consortium BTCRC-GI22-564

A Phase II Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer

Phase I/II Study of Nivolumab in Combination with Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma: BTCRC-HEM15-027

Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111

A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

A Randomized, Multi-Cohort Phase II Trial of Temozolomide and Atezolizumab as Second Line Treatment for Small Cell Lung Cancer